Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The protein-protein interaction between menin and mixed lineage leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the nucleophosmin 1 (NPM1) gene. As a step toward clinical translation of menin-MLL1 inhibitors, we report development of MI-3454, a highly potent and orally bioavailable inhibitor of the menin-MLL1 interaction. MI-3454 profoundly inhibited proliferation and induced differentiation in acute leukemia cells and primary patient samples with MLL1 translocations or NPM1 mutations. When applied as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia, including patient-derived xenograft models, through downregulation of key genes involved in leukemogenesis. We also identified MEIS1 as a potential pharmacodynamic biomarker of treatment response with MI-3454 in leukemia, and demonstrated that this compound is well tolerated and did not impair normal hematopoiesis in mice. Overall, this study demonstrates, for the first time to our knowledge, profound activity of the menin-MLL1 inhibitor as a single agent in clinically relevant PDX models of leukemia. These data provide a strong rationale for clinical translation of MI-3454 or its analogs for leukemia patients with MLL1 rearrangements or NPM1 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 10×
“Coexistence of the FLT3-ITD and NPM1 mutations defines the most unfavorable category of NPM1 mutated AMLs (30), with an overall survival rate below 50% (31, 32), emphasizing the need for new therapies.”
BackgroundInfluentialCytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892 · cited 1×
“mutations are found in over 30% of AML patients (25, 26) and are associated with the upregulated expression of HOXA, HOXB and MEIS1 genes (24, 27, 28).”
BackgroundRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 1×
“4, 5, 43), preclinical activity of these agents has not been reported in PDX models of MLL leukemia.”
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628 · cited 2×
“Coexistence of the FLT3-ITD and NPM1 mutations defines the most unfavorable category of NPM1 mutated AMLs (30), with an overall survival rate below 50% (31, 32), emphasizing the need for new therapies.”
BackgroundTransformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“MLL1 translocations lead to fusion of the N-terminal fragment of MLL1 with one of over 60 protein partners (11-13), resulting in the expression of MLL fusion proteins that enhance proliferation and block hematopoietic differentiation, ultimately driving the development of leukemia (14).”
Self-citationPotent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722 · cited 1×
“4, 5, 43), preclinical activity of these agents has not been reported in PDX models of MLL leukemia.”
He, S., Senter, T. J., Pollock, J., Han, C., Upadhyay, S. K., Purohit, T., Gogliotti, R. D., Lindsley, C. W., Cierpicki, T., Stauffer, S. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401868d · Cited by 99 · cited 1×
“We found that MI-3454 markedly reduced the previous work has resulted in the development of first-in-class small-molecule inhibitors of the menin-MLL1 interaction, which directly bind to the MLL1 binding site on menin and block this protein-protein interaction (17–23).”
Self-citation
Cited by
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
NPM1-mutated acute myeloid leukemia: from bench to bedside
Falini, B., Brunetti, L., Sportoletti, P., & Martelli, M. P. (2020) · Blood · doi:10.1182/blood.2019004226 · Cited by 337
Towards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
Recent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 275
Metadata
- Authors
- Klossowski, S., Miao, H., Kempinska, K., Wu, T., Purohit, T., Kim, E., Linhares, B. M., Chen, D., Jih, G., Perkey, E., Huang, H., He, M., Wen, B., Wang, Y., Yu, K., Lee, S. C.-W., Danet-Desnoyers, G., Trotman, W., Kandarpa, M., Cotton, A., Abdel-Wahab, O., Lei, H., Dou, Y., Guzman, M., Peterson, L., Gruber, T., Choi, S., Sun, D., Ren, P., Li, L.-S., Liu, Y., Burrows, F., Maillard, I., Cierpicki, T., & Grembecka, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-01-21
- Volume
- 130
- Issue
- 2
- Pages
- 981-997
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4242135586
- Cited by
- 246
- References
- 7
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. https://app.cochat.ai/papers/10.1172/jci129126
- The paper
- Klossowski, S., Miao, H., Kempinska, K., Wu, T., Purohit, T., Kim, E., Linhares, B. M., Chen, D., Jih, G., Perkey, E., Huang, H., He, M., Wen, B., Wang, Y., Yu, K., Lee, S. C.-W., Danet-Desnoyers, G., Trotman, W., Kandarpa, M., . . . Grembecka, J. (2020). Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. Journal of Clinical Investigation. https://doi.org/10.1172/jci129126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.